141 related articles for article (PubMed ID: 31679948)
1. PD-1 immunotherapy for recurrent or metastatic HNSCC.
Ferris RL; Licitra L
Lancet; 2019 Nov; 394(10212):1882-1884. PubMed ID: 31679948
[No Abstract] [Full Text] [Related]
2. Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck.
Shetty AV; Wong DJ
Otolaryngol Clin North Am; 2017 Aug; 50(4):775-782. PubMed ID: 28755705
[TBL] [Abstract][Full Text] [Related]
3. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
Huang LL; Shi YK
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
5. PD-1 inhibition enters the frontline.
Killock D
Nat Rev Clin Oncol; 2020 Feb; 17(2):69. PubMed ID: 31729474
[No Abstract] [Full Text] [Related]
6. [Pembrolizumab is more effective and better tolerable than methotrexate, docetaxel, or cetuximab in recurrent or metastatic HNSCC (KEYNOTE-040)].
Hermann RM; Christiansen H
Strahlenther Onkol; 2019 Sep; 195(9):851-854. PubMed ID: 31250051
[No Abstract] [Full Text] [Related]
7. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab for the treatment of head and neck squamous cell cancer.
Ho WJ; Mehra R
Expert Opin Biol Ther; 2019 Sep; 19(9):879-885. PubMed ID: 31317798
[No Abstract] [Full Text] [Related]
9. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
10. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Yearley JH; Gibson C; Yu N; Moon C; Murphy E; Juco J; Lunceford J; Cheng J; Chow LQM; Seiwert TY; Handa M; Tomassini JE; McClanahan T
Clin Cancer Res; 2017 Jun; 23(12):3158-3167. PubMed ID: 28619999
[No Abstract] [Full Text] [Related]
11. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
Specenier P; Vermorken JB
Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P; Vermorken JB
BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
[TBL] [Abstract][Full Text] [Related]
13. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
Moy JD; Moskovitz JM; Ferris RL
Eur J Cancer; 2017 May; 76():152-166. PubMed ID: 28324750
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy: Who Is Eligible?
Wang D; Gilbert J; Kim YJ
Otolaryngol Clin North Am; 2017 Aug; 50(4):867-874. PubMed ID: 28755708
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for recurrent/metastatic head and neck cancer.
Alfieri S; Cavalieri S; Licitra L
Curr Opin Otolaryngol Head Neck Surg; 2018 Apr; 26(2):152-156. PubMed ID: 29432222
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.
Lala M; Chirovsky D; Cheng JD; Mayawala K
Oral Oncol; 2018 Sep; 84():108-120. PubMed ID: 30115469
[TBL] [Abstract][Full Text] [Related]
17. Increased PD-1
Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
Sheth S; Weiss J
Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
[TBL] [Abstract][Full Text] [Related]
19. Afatinib in squamous cell carcinoma of the head and neck.
Specenier P; Vermorken J
Expert Opin Pharmacother; 2016 Jun; 17(9):1295-301. PubMed ID: 27160335
[TBL] [Abstract][Full Text] [Related]
20. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]